Nutriband's Trademark Allowance Advances Abuse-Deterrent Fentanyl Patch
Found this article helpful?
Share it with your network and spread the knowledge!

Nutriband Inc. (NASDAQ: NTRB), a Texas-based developer of transdermal pharmaceutical products, announced it has received a Notice of Allowance dated Nov. 3, 2026, from the United States Patent and Trademark Office for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company said it intends to pursue full trademark registration in the United States and internationally and is preparing to submit its proposed global brand name to the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities for preapproval review. For investors and industry observers, the allowance matters because it secures naming rights for a product that could address a persistent public health challenge while carrying significant commercial potential.
Nutriband’s lead product incorporates its proprietary AVERSA technology, designed to deter intentional abuse and misuse of fentanyl patches while reducing accidental exposure risks. The company’s naming process emphasizes minimizing potential medication errors associated with similar-looking or similar-sounding drug names, a detail that is especially important for high-risk transdermal opioids. Nutriband estimates potential peak annual U.S. sales of $80 million to $200 million for the product and is pursuing development for international markets. The AVERSA technology uses aversive agents in transdermal patches to discourage misuse of medications with abuse potential, including opioids and stimulants, and is supported by patents issued in 46 countries.
The economic implications extend beyond Nutriband. Texas has become a hub for life sciences and biotech communications, and the company’s progress adds to the state’s growing profile in pharmaceutical innovation. For the broader industry, a successfully commercialized abuse-deterrent fentanyl patch could set a new standard for transdermal drug safety and reduce costs associated with misuse and accidental exposure. The global trademark strategy also signals Nutriband’s ambition to compete in international markets, where regulatory pathways can be lengthy and complex.
Investors can track the company’s latest news and updates through its newsroom at https://ibn.fm/NTRB, and the full press release is available at https://ibn.fm/FN3Or. The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, along with social media distribution and corporate communications solutions. Nutriband’s website is www.nutriband.com.
The Notice of Allowance is not a final registration, but it represents a key milestone in the commercialization timeline. For a product with abuse-deterrent claims, brand clarity and regulatory acceptance of naming are foundational to market entry. Nutriband’s focus on international trademark protection also suggests it is laying groundwork for partnerships or direct sales outside the United States. As the opioid crisis continues to shape public policy and healthcare spending, technologies that reduce abuse and accidental exposure could gain traction with regulators, payers and providers. For Texas, the news reinforces the state’s role as a base for companies developing solutions with national and global reach.
